Development asset linked to Prime Medicine in public FDA and regional records.
biotech · Advanced Solid Tumors · Seasonal Allergic Rhinitis · PRME
Prime Medicine
Prime Medicine drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
60 First St, Cambridge, Massachusetts 02141, US HQ
2019 Founded
185 Employees
Public company Type
PRME · NYSE Ticker
Company details
- Status
- Public
- HQ
- 60 First St, Cambridge, Massachusetts 02141, US
- Founded
- 2019
- Employees
- 185
- Programs
- 17
- Drugs
- 6
- Patents
- 127
Prime Medicine pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Prime Medicine drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Prime Medicine's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Prime Medicine in public FDA and regional records.
-
Development asset linked to Prime Medicine in public FDA and regional records.
-
Development asset linked to Prime Medicine in public FDA and regional records.